Illumina, Inc. / Pacific Biosciences of California, Inc. merger inquiry

The CMA is investigating the anticipated acquisition by Illumina, Inc. of Pacific Biosciences of California, Inc.

Phase 2

Administrative timetable

Date of referral: 27 June 2019

Statutory deadline: 11 December 2019

Contact

Illumina_PacBio@cma.gov.uk

Third party submissions

Issues statement

1 August 2019: The issues statement sets out the scope of the inquiry. It outlines initial theories on what might be adversely affecting competition, but it does not set out findings or conclusions. The deadline for submissions on the issues statement is 5pm, Thursday 15 August 2019.

Merger notice

Response to phase 1 decision

Inquiry group appointed

27 June 2019: The CMA has appointed the inquiry group:

Stuart McIntosh (Chair), Humphrey Battcock, Colleen Keck and John Thanassoulis

Terms of reference

27 June 2019: the CMA has referred the anticipated acquisition by Illumina, Inc. of Pacific Biosciences of California, Inc. for an in-depth investigation.

Phase 1

Statutory timetable

Phase 1 date Action
18 June 2019 Decision announced
17 April 2019 Launch of merger inquiry
17 April to 3 May 2019 Invitation to comment

Reference decision

27 June 2019: The CMA has referred the anticipated acquisition by Illumina Inc. of Pacific Biosciences of California, Inc. for an in-depth investigation, on the basis that, on the information currently available to it, it is or may be the case that this merger has resulted or may be expected to result in a substantial lessening of competition within a market or markets in the United Kingdom.

Reference unless undertakings accepted

18 June 2019: The CMA has decided, on the information currently available to it, that it is or may be the case that this merger has resulted or may be expected to result in a substantial lessening of competition within a market or markets in the United Kingdom. This merger will be referred for a phase 2 investigation unless the parties offer acceptable undertakings to address these competition concerns.

Launch of merger inquiry

17 April 2019: The CMA announced the launch of its merger inquiry by notice to the parties.

Invitation to comment: closes 3 May 2019

17 April 2019: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.

Contact

Please send written representations about any competition issues to:

Kalani Herath
Competition and Markets Authority
The Cabot
25 Cabot Square
London
E14 4QZ

kalani.herath@cma.gov.uk

Or

Alexandra Hazell
Competition and Markets Authority
The Cabot
25 Cabot Square
London
E14 4QZ

alex.hazell@cma.gov.uk

Published 17 April 2019
Last updated 11 September 2019 + show all updates
  1. Third party submission published.
  2. Published: Issues statement, merger notice, administrative timetable, and parties’ response to phase 1 decision.
  3. Decision to refer and terms of reference published.
  4. Commencement of initial period notice published
  5. First published.